Amphista Therapeutics operates as a biopharmaceutical company.
Amphista Therapeutics operates as a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease causing proteins.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 13, 2022 | Series B | — | 1 | Dementia Discovery Fund | — | Detail |
Mar 17, 2021 | Series B | $53M | 6 | Forbion Capital Partners Gilde Healthcare | — | Detail |
Apr 7, 2020 | Series A | $7.50M | 4 | Advent Life Sciences | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Dementia Discovery Fund | Yes | Series B |
Forbion Capital Partners | Yes | Series B |
Gilde Healthcare | Yes | Series B |
Advent Life Sciences | — | Series B |
BioMotiv | — | Series B |
Eli Lilly & Company Foundation | — | Series B |
Novartis Venture Fund | — | Series B |
European Investment Fund | — | Series A |
Scottish Investment Bank | — | Series A |